30.09.2011 - ViroPharma announced the license of worldwide rights from Intellect Neurosciences to its clinical stage drug candidate, OX1, being developed for the treatment of Friedreich's...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)
